Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference

Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) —

Biora Therapeutics, Inc

. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be presenting and participating in one-on-one meetings at the H.C. Wainwright 24

th

Annual Global Investment Conference, which is taking place both virtually and at the Lotte New York Palace Hotel in New York City, September 12-14, 2022.

Investors who are interested in meeting with Biora at the conference should reach out to their H.C. Wainwright representative to schedule a meeting.


About Biora Therapeutics


Biora Therapeutics is the biotech company that is reimagining therapeutics. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.

For more information, visit

bioratherapeutics.com

or follow the company on

LinkedIn

or

Twitter

.


Safe Harbor Statement or Forward-Looking Statements


This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.


Investor Contact


Chuck Padala

Managing Director, LifeSci Advisors


[email protected]


(646) 627-8390


Media Contact



[email protected]

Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference


Primary Logo

Featured image: Megapixl © Ipopba

Disclaimer